The efficacy of standard laxative use for the prevention and treatment of opioid induced constipation during oxycodone use: a small Dutch observational pilot study

References

• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.
   PubMed Web of Science ®Google Scholar
• Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin. 2011;27:449–462.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Pergolizzi JV Jr. A modern analgesics pain ‘pyramid’. J Clin Pharm Ther. 2014;39:4–6.
   PubMed Web of Science ®Google Scholar
• Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181–1187.
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–671.
   PubMed Web of Science ®Google Scholar
• Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009;5:137–144.
   PubMedGoogle Scholar
• Dunlop W, Uhl R, Khan I, et al. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ. 2012;15:564–575.
   PubMedGoogle Scholar
• Kwong WJ, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010;44:630–640.
   PubMed Web of Science ®Google Scholar
• Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010;19:44–51.
   PubMedGoogle Scholar
• Hjalte F, Berggren AC, Bergendahl H, et al. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage. 2010;40:696–703.
   PubMed Web of Science ®Google Scholar
• Abramowitz L, Beziaud N, Labreze L, et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013;16:1423–1433.
   PubMedGoogle Scholar
• Camilleri M, Drossman DA, Becker G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26:1386–1395.
   PubMed Web of Science ®Google Scholar
• Chau DL, Walker V, Pai L, et al. Opiates and elderly: use and side effects. Clin Interv Aging. 2008;3:273–278.
   PubMed Web of Science ®Google Scholar
• Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105–S120.
   PubMed Web of Science ®Google Scholar
• Adriaensen H, Vissers K, Noorduin H, et al. Opioid tolerance and dependence: an inevitable consequence of chronic treatment? Acta Anaesthesiol Belg. 2003;54:37–47.
   PubMedGoogle Scholar
• Boswell K, Kwong WJ, Kavanagh S. Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: a systematic literature review. J Opioid Manag. 2010;6:269–289.
   PubMedGoogle Scholar
• Coyne KS, LoCasale RJ, Datto CJ, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269–281.
   PubMedGoogle Scholar
• Diego L, Atayee R, Helmons P, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011;20:1047–1056.
   PubMed Web of Science ®Google Scholar
• Graeff=de A, Jobse A, Krol RJA. Obstipatie bij patiënten met kanker. Mod Med. 2010;34:26–30.
   Google Scholar
• Holzer P. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal? Curr Pharm Des. 2012;18:6010–6020.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015 Nov 19. DOI:10.1111/pme.12937. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015;8:206–220.
   PubMed Web of Science ®Google Scholar
• Landelijke Richtlijnwerkgroep Pijn bij Kanker. [ Cancer Pain] Pijn bij kanker, Landelijke richtlijn versie 1.1 [Internet]. 2008 [cited 2015 Dec 2]. Available from: http://oncoline.nl/pijn-bij-kanker IKNL. 1–172.
   Google Scholar
• Diemel JM, Van Den Hurk APJM, Muris JWM, et al. NHG-Standaard Obstipatie. Huisarts Wet. 2010;53:484–498.
   Google Scholar
• Warle-van Herwaarden MF, Kramers C, Sturkenboom MC, et al. Targeting outpatient drug safety: recommendations of the Dutch HARM-Wrestling Task Force. Drug Saf. 2012;35:245–259.
   PubMed Web of Science ®Google Scholar
• SFK. Kwaliteitsindicatoren met (een) KISS. Pharm Weekbl. 2009;144(21):11.
   Google Scholar
• [Institute for Rational Use of Medicines] (IVM). Monitor Voorschrijfgedrag huisartsen [Monitor Prescribing Behaviour Practitioners] [Internet]. 2014 [cited 2015 Dec 2]. Available from: https://www.medicijngebruik.nl/content/products%5C1784%5Cattachments/rap_monitor_voorschrijfgedrag_huisartsen_2014_20141113_s.pdf
   Google Scholar
• Couteau AMCM, Arkink JK, Keyzer JJ, et al. Kwaliteitsjaarraport 2013–2014 [Quality year report 2013–2014] [Internet]. Stratumse apotheek; 2014 [cited 2015 Dec 2]. Available from: http://www.stratumseapotheek.nl/filedownload/default.aspx?fileType=FM&ID=104892
   Google Scholar
• Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008;62:1159–1167.
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26:50–60.
   PubMed Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9:1144–1154.
   PubMed Web of Science ®Google Scholar
• Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24:3503–3512.
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56–64.
   PubMed Web of Science ®Google Scholar
• Lowenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10:531–543.
   PubMed Web of Science ®Google Scholar
• Lowenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol. 2010;10:12.
   PubMedGoogle Scholar
• Rentz AM, Yu R, Muller-Lissner S, et al. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12:371–383.
   PubMedGoogle Scholar
• Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol. 2010;23:616–622.
   PubMed Web of Science ®Google Scholar
• Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol. 2015;49:9–16.
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Muller-Lissner S, Buschmann-Kramm C, et al. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res. 2011;39:41–50.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–924.
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11S–18S.
   PubMed Web of Science ®Google Scholar
• Mueller-Lissner S. Opioid-induced constipation-mechanisms, relevance and management. Eu Gastroenterol Hepatol Rev. 2010;6:54–57.
   Google Scholar
• Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs. 2011;20:427–439.
   PubMed Web of Science ®Google Scholar
• Schoorl J, Zylicz Z. [Laxative policy for terminal patients ineffective]. Ned Tijdschr Geneeskd. 1997;141:823–826.
   PubMedGoogle Scholar
• Miles CL, Fellowes D, Goodman ML, et al. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2006;(4):CD003448.
   Google Scholar
• Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD003448.
   Google Scholar
• Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35–42.
   PubMed Web of Science ®Google Scholar